INTRODUCTION
The Philadelphia (Ph) chromosome resulting from a reciprocal translocation between chromosomes 9 and 22 and leading to the expression of the oncogenic protein, BCR-ABL, occurs in about a quarter to a third of adult patients with acute lymphoblastic leukemia (ALL). 1 Prior to the introduction of the BCR-ABL specific tyrosine kinase inhibitors, the outcome of patients with this disease was poor with long term survival occurring almost exclusively in patients who underwent an allogeneic stem cell transplant (SCT) in first complete remission (CR). 2 With the introduction of effective tyrosine kinase inhibitors (TKI), the outcome of patients has significantly improved and whether allogeneic SCT is a necessary component of therapy for all patients with Ph+ ALL has been questioned. In early reports many patients who received the TKI/cytotoxic chemotherapy combinations and who were unable to receive an allogeneic SCT in first CR, had durable remissions. [3] [4] [5] Further follow-up reports of some of these studies have, however, suggested an advantage for undergoing an allogeneic SCT in first CR, at least in the younger age group. However, in a retrospective analysis from the Children's Oncology Group, patients who received long-term continuous imatinib plus chemotherapy but no allogeneic SCT had a better, but statistically similar outcome to those who underwent HLA-matched sibling or unrelated donor SCT. 6 Clearly, these chemotherapy/TKI combination regimens are providing an alternate approach for patients who are unable to undergo allogeneic SCT in first
For personal use only. on March 31, 2017. by guest www.bloodjournal.org From CR. In large studies of patients with Ph+ ALL reported to date, this comprises a substantial proportion of patients. 7 Whether these patients should be considered for alternative SCT options such as reduced intensity allogeneic SCT in the older patients or antigen mismatch unrelated donor (MMUD), haploidentical, or cord blood SCT for patients without a sibling or matched unrelated donor, remains debatable. 8 Clearly, a strategy identifying patients who are more likely to relapse, may allow the selection of patients for the higher risk SCT procedures while sparing those with minimal likelihood of relapse from the potential complications of such transplants.
In recent years, monitoring minimal residual disease (MRD) has been increasingly utilized in childhood and adult ALL with a number of studies demonstrating its importance as an independent prognostic factor. 9 Bassan et al.
used real-time quantitative polymerase chain reaction (RQ-PCR) for leukemiaspecific antigens using probes for the VDJ/VJ regions of immunoglobulin heavy In this study, we evaluated the predictive value of MRD assessment by RQ-PCR (for BCR-ABL transcripts and for the immunoglobulin heavy chain gene clonality, IGH) and by multi-parameter flow cytometry (MFC) in patients with Ph+ ALL treated with combination chemotherapy and TKIs, but without an allogeneic stem cell transplant, on two frontline protocols conducted at our institution. Three different methods for MRD assessment were utilized to determine whether any one is superior to the others for predicting outcome.
PATIENTS AND METHODS

Patients
From April 2001 to March 2011, 122 patients with newly diagnosed Ph+ ALL were treated with one of the two frontline regimens combining hyperCVAD with imatinib (n= 54) or dasatinib (n=68).
3,5 115 (94%) achieved CR, 2 (2%) CR without peripheral blood count recovery, and 1 (1%) partial response; 4 (3%) patients died at induction. Among the patients achieving CR, 14 achieved it with two cycles of therapy, and were excluded as they were already established as being at a higher risk of relapse. Therefore, 101 patients achieved CR with one induction course and had at least one minimal residual disease (MRD) assessment; 25 patients underwent an allogeneic stem cell transplant in first CR and were also excluded from the analysis in order to arrive at a more uniform population with regards to relapse and survival, and the role of allogeneic stem cell transplant in first CR. The overall characteristics of the final 76 patients are shown in Table 1 . All patients signed an approved informed consent form to participate in the trials in accordance with the Declaration of Helsinki. The two clinical trials that the study is based upon were approved by the institutional review board of The University of Texas -MD Anderson Cancer Center.
Treatment regimens
The details of the two regimens have been published previously. 
Response and outcome definitions
Complete response (CR) was defined as the presence of less than 5% blasts in the bone marrow (BM) with more than 1x10 and therefore a negative result must be interpreted with caution. However, many
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MRD by polymerase chain reaction (PCR)
BCR-ABL RQ-PCR was performed on total RNA extracted from leukocytes following red blood cell lysis. Reverse transcription was performed using random hexamers and PCR performed using TaqMan primer/probes for the e1a2, e13a2 (b2a2), and e14a2 (b3a2) BCR-ABL transcripts in a single tube with normalization to total ABL transcripts. Post-PCR capillary electrophoresis was used to type splice form, with the method having a sensitivity of approximately 1 in 10 5 BCR-ABL expressing cells as established by periodic dilution studies. 15 Specimens were considered as suboptimal when BCR-ABL fusion transcripts were not detected (negative) and ABL copies were below < 10 4 ; these specimens were not included in the study. Major molecular response (MMR) was defined as a BCR-ABL/ABL ratio of less than 0.1%. Values were standardized to the international scale.
IGH-PCR was performed using variable region framework 1, 2 and 3 primers, each in combination with fluorescent dye , 6-carboxyfluorescein (FAM) labeled JH1245 consensus primer and JH3 specific primer as described previously. 16, 17 The fluorescent labeled products were subjected to capillary electrophoresis and Genescan analysis. At least one clonal rearrangement was seen in all patients. Though allele specific IGH-PCR is specific and more sensitive for MRD assessment, this requires sequencing the clone and designing clone specific primers for each patient. Hence, though less sensitive, due to tedious nature of allele specific PCR, we limited our assessment to simpler capillary electrophoresis and genescan approach. Using this method, the sensitivity of detection of MRD in a sample with low numbers of polyclonal B cells (such as post-treatment bone marrow) is approximately 0.2% to 1%.
Statistical methods
Patient characteristics were summarized using the median (range) for numerical variables and frequencies (percentages) for categorical variables.
Associations between categorical variables were assessed using Fisher exact tests. The Kaplan and Meier (KM) method was used to estimate the hazard functions of overall survival and disease-free survival, and the two-sided log-rank test was used to compare the hazard functions between groups. Event-free survival was defined as time to disease relapse or death, whichever came first.
Multivariate Cox proportional hazards (PH) models were used to assess the event-free survival by MMR, IGH, and MFC as time-dependent variables respectively, adjusting for other baseline covariates. The cumulative incidence of relapse was estimated using competing risk analysis for death and relapse.
RESULTS
Treatment outcomes and follow-up
These studies were sequential frontline protocols for patients with Ph+ For
Multivariate analysis on clinical predictors of outcome
We sought to identify characteristics at presentation that could predict relapse-free and overall survival. WBC at presentation, platelet count, percentage of bone marrow blasts, presence of abnormalities in addition to Ph, type of fusion transcript (e1a2 or e1a3 vs. e13a2 and e14a2), CD20 expression, and time to achieving hematological and cytogenetic CR were evaluated. Only WBC at presentation was significantly associated with a better event-free survival (Table 2 ). Due to the use of MMR, IGH and MFC as internal time-dependent covariates in the multivariate model, the interpretation of the effects for baseline covariates in Table 2 needs to be cautious.
MRD by MFC as a predictor of CR duration and overall survival
We evaluated the predictive value of detecting MRD by MFC at various (Figures 2c and 2d) . Furthermore, patients who were negative at 12 months had a significantly longer survival and CR duration (p=0.001 and p=0.0001, respectively) (Figures 2e and 2f) .
BCR-ABL ratio as a predictor of CR duration and overall survival.
We examined the predictive value of achieving a major molecular response (MMR; BCR-ABL-ABL<0.1%) at various time points, for CR duration, event-free and overall survival. We used MMR as a cut-off for several reasons.
First, we have 7 patients with MMR who have remained in CR several years after completion of therapy. Overall, 47 (62%) of patients achieved complete molecular remission (CMR) some time between achieving morphological CR and 12 months. Twenty four (32%) achieved MMR and 4 (5%) never achieved MMR or better. When we analyzed the data by MMR vs. CMR, there was no difference in the outcome of these patients (supplemental Table and Figure 5 ). Although achieving MMR at CR was associated with longer CR duration and overall survival, these did not reach statistical significance (Figures 3a and 3b) .
Achieving MMR at 3 and 6 months was associated with a significantly higher likelihood of longer survival (Figures 3c and 3d) . Similarly, achieving MMR or better at 9 and 12 months was associated with longer survival (Figures 3e and   3f ) and although CR duration was longer for the patients achieving MMR at these time points, it did not reach statistical significance (Figures not included) . For 
MRD by IGH PCR as a predictor of CR duration and overall survival
There was no association between achieving a negative IGH PCR at any time point and improved disease-free and overall survival. This may be due to the use of consensus rather than leukemia specific primers in this study.
Cumulative incidence of relapse using competing risk analysis (survival and relapse):
The cumulative incidence of relapse was estimated using competing risk analysis for death and relapse. There was no difference in the cumulative incidence of relapse by achieving MMR, or achieving MFC and IGH PCR negativity at any of the time points investigated with the exception of achieving a flow negative status by 3 months that was associated with a lower incidence of relapse (Figure 4) .
Concordance of MRD testing using different techniques
Fifteen patients had one or more specimens (total of 27 specimens) positive for BCR-ABL transcripts (>0.1%) but negative for MRD by MFC (supplemental Table 2 ). These discordances were not due to inadequate MFC specimen cell counts. Multi-lineage involvement with the presence of the Ph chromosome in B-and T-lymphoid, erythroid and myeloid cells has been previously described 18 and may well account for these discrepancies. This is an important consideration in the interpretation of MRD data in patients with Ph positive ALL.
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DISCUSSION
The potential role of MRD detection after induction and consolidation in predicting the outcome has been increasingly evaluated in patients with ALL. 9 A number of studies in both children and adults using either MFC or PCR-based methods have clearly demonstrated the ability to detect MRD and its potential role for stratifying the risk of relapse. 17, [19] [20] [21] [22] [23] [24] [25] [26] [27] Multiple clinical trials incorporating imatinib and dasatinib into the frontline regimens used for treating patients with ALL, have clearly established the superiority of this approach over comparable regimens without these TKIs.
2,28
The majority of these trials have included imatinib, which in combination with traditional cytotoxic agents has produced higher CR rates and better long-term outcomes. 28 Although dasatinib is a more potent inhibitor of the kinase activity of Although all 53 patients enrolled in the study achieved CR, with a follow-up of 20 months, 23 patients had relapsed and 12 of 17 patients with mutational analysis had a T315I mutation. 29 Of interest, on multivariate analysis, BCR-ABL level of < 10 -3 at day 85 correlated with disease-free survival. 29 In our study of dasatinib with chemotherapy, with a median follow-up of 14 months, 5 of 35 patients had relapsed including one with the T315I mutation. 
In this study, we attempted to establish whether achieving MMR or negative status for MRD by MFC and by IGH PCR, could predict the outcome in a small cohort of patients with Ph+ ALL treated with combination of chemotherapy and TKIs without an allogeneic stem cell transplant. We were able to demonstrate that achieving MMR and negative MFC status at 3 months (and beyond) from starting treatment were associated with a decreased likelihood of relapse and with a longer overall survival. However, achieving a negative status for IGH by PCR did not predict for an improved outcome (data not shown). This may be attributable to the use of consensus rather than leukemia-specific primers in this study. We then estimated the cumulative incidence of relapse using competing risk analysis (death and relapse) and were able to demonstrate that achieving a negative MRD status by MFC at 3 months was associated with a statistically significant reduction in the risk of relapse (p=.039; Figure 4 ). This was not true for achieving MMR or better, or negative IGH PCR at 3 months (p=.93 and p=.92; data not shown). However, using achievement of MMR, negative We note that 15 patients had one or more specimens (total of 27 specimens) positive for BCR-ABL transcripts (>0.1%) but negative for MRD by MFC (supplemental Table 2 ). These discordances were not due to inadequate MFC specimen cell counts. All subsequent relapse specimens contained CD19+ blast populations with antigenic aberrancies demonstrable using the same analysis strategies used on the specimens assessed for MRD. Several MRD specimens had high transcript levels (BCR-ABL/ABL transcript ratios of >20%), but fewer than 1% CD19+ cells by MFC, strongly suggesting that the residual Ph+ cells were present in a non-ALL compartment. 18 These data clearly support the role of monitoring for MRD by MFC and by PCR for BCR-ABL in patients with Ph+ ALL who receive regimens containing TKIs. Whether these data can be used to determine whether an alternative donor transplant should be performed in first remission will require larger studies and collaborative international efforts to arrive at more concrete conclusions.
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